Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Gewählte Publikation:

Open Access Logo

Publikationstyp: Zeitschriftenaufsatz
Dokumenttyp: Originalarbeit

Jahr: 2019

AutorInnen: Menzl, I; Zhang, T; Berger-Becvar, A; Grausenburger, R; Heller, G; Prchal-Murphy, M; Edlinger, L; Knab, VM; Uras, IZ; Grundschober, E; Bauer, K; Roth, M; Skucha, A; Liu, Y; Hatcher, JM; Liang, Y; Kwiatkowski, NP; Fux, D; Hoelbl-Kovacic, A; Kubicek, S; Melo, JV; Valent, P; Weichhart, T; Grebien, F; Zuber, J; Gray, NS; Sexl, V

Titel: A kinase-independent role for CDK8 in BCR-ABL1+ leukemia.

Quelle: Nat Commun. 2019; 10(1):4741



Autor/innen der Vetmeduni Vienna:

Berger-Becvar Angelika
Edlinger Leo
Fux Daniela
Grausenburger Reinhard
Grebien Florian
Grundschober Eva
Hölbl-Kovacic Andrea
Knab Vanessa-Maria
Menzl Ingeborg
Prchal-Murphy Michaela
Sexl Veronika
Uras Jodl Iris

Beteiligte Vetmed-Organisationseinheiten
Institut für Medizinische Biochemie
Institut für Pharmakologie und Toxikologie


Zugehörige(s) Projekt(e): Stat1onieren Irf1 in Mammakarzinogenese und Therapie

CDK 8 in der NK Zell vermittelten Leukämieüberwachung


Abstract:
Cyclin-dependent kinases (CDKs) are frequently deregulated in cancer and represent promising drug targets. We provide evidence that CDK8 has a key role in B-ALL. Loss of CDK8 in leukemia mouse models significantly enhances disease latency and prevents disease maintenance. Loss of CDK8 is associated with pronounced transcriptional changes, whereas inhibiting CDK8 kinase activity has minimal effects. Gene set enrichment analysis suggests that the mTOR signaling pathway is deregulated in CDK8-deficient cells and, accordingly, these cells are highly sensitive to mTOR inhibitors. Analysis of large cohorts of human ALL and AML patients reveals a significant correlation between the level of CDK8 and of mTOR pathway members. We have synthesized a small molecule YKL-06-101 that combines mTOR inhibition and degradation of CDK8, and induces cell death in human leukemic cells. We propose that simultaneous CDK8 degradation and mTOR inhibition might represent a potential therapeutic strategy for the treatment of ALL patients.

Keywords Pubmed: Animals
Cell Line, Tumor
Cell Survivaldrug effectsgenetics
Cyclin-Dependent Kinase 8antagonists & inhibitorsgeneticsmetabolism
Disease Models, Animal
Fusion Proteins, bcr-ablantagonists & inhibitorsgeneticsmetabolism
Humans
Mice, Inbred C57BL
Mice, Inbred NOD
Mice, Knockout
Mice, SCID
Mice, Transgenic
Precursor B-Cell Lymphoblastic Leukemia-Lymphomadrug therapygeneticsmetabolism
Protein Kinase Inhibitorspharmacology
Signal Transductiondrug effectsgenetics
Small Molecule Librariespharmacology
TOR Serine-Threonine Kinasesantagonists & inhibitorsgeneticsmetabolism

© Veterinärmedizinische Universität Wien Hilfe und DownloadsErklärung zur Barrierefreiheit